What can rheumatologists learn from translational cancer therapy?

Arthritis Research and Therapy

Volumn 15, Issue 3, 2013, Pages

  Sherlock, Jonathan P ^a,b   Filer, Andrew D ^a   Isaacs, John D ^c   Buckley, Christopher D ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOIMMUNE DISEASE; BLADDER CANCER; CANCER THERAPY; CROHN DISEASE; DIGESTIVE SYSTEM INFLAMMATION; HELICOBACTER INFECTION; HEPATITIS C VIRUS; HUMAN; INFECTION; INFLAMMATION; LEARNING; LIVER CANCER; LYMPHOMA; METASTASIS; NEOPLASM; NOTE; PROBABILITY; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; RISK; SCHISTOSOMIASIS; SJOEGREN SYNDROME; STOMACH CANCER; ULCERATIVE COLITIS; ARTICLE; IMMUNOLOGY; TRANSLATIONAL RESEARCH;

AUTOIMMUNE DISEASES; HUMANS; INFLAMMATION; NEOPLASMS; RHEUMATOLOGY; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84877617129     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4203     Document Type: Note

References (48)

1. Kovács L, Szodoray P, Kiss E. Secondary tumours in Sjogren's syndrome. Autoimmun Rev 2010, 9:203-206. 10.1016/j.autrev.2009.07.002, 19602455.
2. Franklin J, Lunt M, Bunn D, Symmons D, Silman A. Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis. Ann Rheum Dis 2006, 65:617-622. 10.1136/ard.2005.044784, 1798140, 16249224.
3. Fantini M-C, Pallone F. Cytokines: from gut inflammation to colorectal cancer. Curr Drug Targets 2008, 9:375-380. 10.2174/138945008784221206, 18473765.
4. Chiba T, Marusawa H, Ushijima T. Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation. Gastroenterology 2012, 143:550-563. 10.1053/j.gastro.2012.07.009, 22796521.
5. Hirao Y, Kim W-J, Fujimoto K. Environmental factors promoting bladder cancer. Curr Opin Urol 2009, 19:494-499. 10.1097/MOU.0b013e32832eb4ef, 19553820.
6. Kuper H, Adami HO, Trichopoulos D. Infections as a major preventable cause of human cancer. J Intern Med 2000, 248:171-183. 10.1046/j.1365-2796.2000.00742.x, 10971784.
7. Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 2007, 13:1211-1218. 10.1038/nm1649, 17906636.
8. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001, 193:727-740. 10.1084/jem.193.6.727, 2193412, 11257139.
9. Pardanani A. Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management. Am J Hematol 2012, 87:401-411. 10.1002/ajh.23134, 22410759.
10. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management. Am J Hematol 2012, 87:1037-1045. 10.1002/ajh.23282, 23090888.
11. Miyachi K, Ihara A, Hankins RW, Murai R, Maehiro S, Miyashita H. Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia. Clin Rheumatol 2003, 22:329-332. 10.1007/s10067-003-0716-3, 14576993.
12. Pereira I, Fialho S, Castro G, Zimmermann A. Imatinib mesylate induces clinical remission in rheumatoid arthritis. Joint Bone Spine 2010, 77:372-373. 10.1016/j.jbspin.2010.03.014, 20478730.
13. Ames PRJ, Aye WW, Beatty C, O'Reilly D. Imatinib treatment of seropositive arthritis in a young woman with chronic myeloid leukemia. J Rheumatol 2008, 35:1682.
14. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008, 222:162-179. 10.1111/j.1600-065X.2008.00602.x, 18364001.
15. Greten FR, Eckmann L, Greten TF, Park JM, Li Z-W, Egan LJ, Kagnoff MF, Karin M. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004, 118:285-296. 10.1016/j.cell.2004.07.013, 15294155.
16. He G, Karin M. NF-κB and STAT3 - key players in liver inflammation and cancer. Cell Res 2011, 21:159-168. 10.1038/cr.2010.183, 3193410, 21187858.
17. Shchors K, Shchors E, Rostker F, Lawlor ER, Brown-Swigart L, Evan GI. The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1beta. Genes Dev 2006, 20:2527-2538. 10.1101/gad.1455706, 1578676, 16980582.
18. Mertens M, Singh JA. Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol 2009, 36:1118-1125. 10.3899/jrheum.090074, 19447938.
19. Foster JG, Blunt MD, Carter E, Ward SG. Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies. Pharmacol Rev 2012, 64:1027-1054. 10.1124/pr.110.004051, 23023033.
20. LoRusso PM. Mammalian target of rapamycin as a rational therapeutic target for breast cancer treatment. Oncology 2013, 84:43-56. 10.1159/000343063, 23128843.
21. Jena NR. DNA damage by reactive species: Mechanisms, mutation and repair. J Biosci 2012, 37:503-517. 10.1007/s12038-012-9218-2, 22750987.
22. Weitzman SA, Weitberg AB, Clark EP, Stossel TP. Phagocytes as carcinogens: malignant transformation produced by human neutrophils. Science 1985, 227:1231-1233. 10.1126/science.3975611, 3975611.
23. Güngör N, Godschalk RWL, Pachen DM, Van Schooten FJ, Knaapen AM. Activated neutrophils inhibit nucleotide excision repair in human pulmonary epithelial cells: role of myeloperoxidase. FASEB J 2007, 21:2359-2367. 10.1096/fj.07-8163com, 17440118.
24. Sato Y, Takahashi S, Kinouchi Y, Shiraki M, Endo K, Matsumura Y, Kakuta Y, Tosa M, Motida A, Abe H, Imai G, Yokoyama H, Nomura E, Negoro K, Takagi S, Aihara H, Masumura K-I, Nohmi T, Shimosegawa T. IL-10 deficiency leads to somatic mutations in a model of IBD. Carcinogenesis 2006, 27:1068-1073.
25. Brentnall TA, Crispin DA, Rabinovitch PS, Haggitt RC, Rubin CE, Stevens AC, Burmer GC. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology 1994, 107:369-378.
26. Yamanishi Y, Boyle DL, Rosengren S, Green DR, Zvaifler NJ, Firestein GS. Regional analysis of p53 mutations in rheumatoid arthritis synovium. Proc Natl Acad Sci USA 2002, 99:10025-10030. 10.1073/pnas.152333199, 126618, 12119414.
27. Hudson JD, Shoaibi MA, Maestro R, Carnero A, Hannon GJ, Beach DH. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med 1999, 190:1375-1382. 10.1084/jem.190.10.1375, 2195698, 10562313.
28. Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verástegui E, Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56. 10.1038/35065016, 11242036.
29. Sherlock JP, Joyce-Shaikh B, Turner SP, Chao C-C, Sathe M, Grein J, Gorman DM, Bowman EP, McClanahan TK, Yearley JH, Eberl G, Buckley CD, Kastelein RA, Pierce RH, LaFace DM, Cua DJ. IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells. Nat Med 2012, 18:1069-1076. 10.1038/nm.2817, 22772566.
30. Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, Basham B, McClanahan T, Kastelein RA, Oft M. IL-23 promotes tumour incidence and growth. Nature 2006, 442:461-465. 10.1038/nature04808, 16688182.
31. Macciò A, Madeddu C. Inflammation and ovarian cancer. Cytokine 2012, 58:133-147. 10.1016/j.cyto.2012.01.015, 22349527.
32. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. Annu Rev Immunol 2001, 19:163-196. 10.1146/annurev.immunol.19.1.163, 11244034.
33. Ash Z, Emery P. The role of tocilizumab in the management of rheumatoid arthritis. Expert Opin Biol Ther 2012, 12:1277-1289. 10.1517/14712598.2012.707178, 22849354.
34. Rothwell PM, Price JF, Fowkes FGR, Zanchetti A, Roncaglioni MC, Tognoni G, Lee R, Belch JFF, Wilson M, Mehta Z, Meade TW. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012, 379:1602-1612. 10.1016/S0140-6736(11)61720-0, 22440946.
35. Tiano HF, Loftin CD, Akunda J, Lee CA, Spalding J, Sessoms A, Dunson DB, Rogan EG, Morham SG, Smart RC, Langenbach R. Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res 2002, 62:3395-3401.
36. Mercer LK, Davies R, Galloway JB, Low A, Lunt M, Dixon WG, Watson KD, Symmons DPM, Hyrich KL, . British Society for Rheumatology Biologics Register (BSRBR) Control Centre Consortium Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Rheumatology 2013, 52:91-98. 10.1093/rheumatology/kes350, 3521445, 23238979, British Society for Rheumatology Biologics Register (BSRBR) Control Centre Consortium.
37. Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene 2007, 26:3603-3613. 10.1038/sj.onc.1210376, 17530014.
38. Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, Latinis K, Abud-Mendoza C, Szczepanski LJ, Roschmann RA, Chen A, Armstrong GK, Douglass W, Tyrrell H. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 2010, 69:1629-1635. 10.1136/ard.2009.119933, 2938895, 20488885.
39. Madhusudan S, Foster M, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C, Hoare S, Balkwill F, Talbot DC, Ganesan TS, Harris AL. A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer. Clin Cancer Res 2004, 10:6528-6534. 10.1158/1078-0432.CCR-04-0730, 15475440.
40. Madhusudan S, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C, Hoare S, Balkwill F, Ganesan TS. Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer. J Clin Oncol 2005, 23:5950-5959. 10.1200/JCO.2005.04.127, 16135466.
41. Brown ER, Charles KA, Hoare SA, Rye RL, Jodrell DI, Aird RE, Vora R, Prabhakar U, Nakada M, Corringham RE, DeWitte M, Sturgeon C, Propper D, Balkwill FR, Smyth JF. A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Ann Oncol 2008, 19:1340-1346. 10.1093/annonc/mdn054, 18325912.
42. Harrison ML, Obermueller E, Maisey NR, Hoare S, Edmonds K, Li NF, Chao D, Hall K, Lee C, Timotheadou E, Charles K, Ahern R, King DM, Eisen T, Corringham R, DeWitte M, Balkwill F, Gore M. Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol 2007, 25:4542-4549. 10.1200/JCO.2007.11.2136, 17925549.
43. Flavell SJ, Hou TZ, Lax S, Filer AD, Salmon M, Buckley CD. Fibroblasts as novel therapeutic targets in chronic inflammation. Br J Pharmacol 2008, 153(Suppl 1):S241-246. 2268075, 17965753.
44. Mueller MM, Fusenig NE. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004, 4:839-849.
45. Yamanishi Y, Boyle DL, Pinkoski MJ, Mahboubi A, Lin T, Han Z, Zvaifler NJ, Green DR, Firestein GS. Regulation of joint destruction and inflammation by p53 in collagen-induced arthritis. Am J Pathol 2002, 160:123-130. 10.1016/S0002-9440(10)64356-8, 1867134, 11786406.
46. Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, Gopinathan A, Tuveson DA, Fearon DT. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 2010, 330:827-830. 10.1126/science.1195300, 21051638.
47. Maia M, DeVriese A, Janssens T, Moons M, Lories RJ, Tavernier J, Conway EM. CD248 facilitates tumor growth via its cytoplasmic domain. BMC Cancer 2011, 11:162. 10.1186/1471-2407-11-162, 3107809, 21549007.
48. Maia M, de Vriese A, Janssens T, Moons M, van Landuyt K, Tavernier J, Lories RJ, Conway EM. CD248 and its cytoplasmic domain: a therapeutic target for arthritis. Arthritis Rheum 2010, 62:3595-3606. 10.1002/art.27701, 20722022.